Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

The high-grade B-cell lymphomas: double hit and more

Andrew J. Davies

Blood (2024) 144 (25): 2583–2592.

https://doi.org/10.1182/blood.2023020780

Published: 2024

Journal Articles

Delays to Diagnosis of Peripheral T-Cell Lymphoma and Clinical Utility of Molecular Profiling: A UK Multicentre Real-World Study

Blood (2024) 144 (Supplement 1): 4445.

https://doi.org/10.1182/blood-2024-205820

Published: 2024

Journal Articles

Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK

Blood (2024) 144 (Supplement 1): 2342.

https://doi.org/10.1182/blood-2024-200738

Published: 2024

Journal Articles

PET-Based Prognostic Stratification in Primary Mediastinal B-Cell Lymphoma Using the SUV≥4 Segmentation Threshold: A Comparative Analysis of Contouring Methods in the IELSG37 Trial Cohort

Luca Ceriani, Lisa Milan, Maria Cristina Pirosa, Alice Di Rocco, Teresa Ruberto, Luciano Cascione, Peter Johnson, Andrew J. Davies, Maurizio Martelli, Emanuele Zucca

Blood (2024) 144 (Supplement 1): 1712.

https://doi.org/10.1182/blood-2024-206784

Published: 2024

Journal Articles

Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

Blood (2024) 144 (Supplement 1): 3100.

https://doi.org/10.1182/blood-2024-203781

Published: 2024

Journal Articles

Golseek-2: A Phase 2 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma

Jose C. Villasboas Bisneto, Pier Luigi Zinzani, Andrew J. Davies, Robert Kridel, Guilherme Fleury Perini, Parth Rao, Joanna Mikita-Geoffroy, Akshay Sudhindra, Charalambos Andreadis

Blood (2024) 144 (Supplement 1): 4422.2.

https://doi.org/10.1182/blood-2024-203181

Published: 2024

Journal Articles

Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

Blood (2024) 144 (Supplement 1): 235.

https://doi.org/10.1182/blood-2024-199710

Published: 2024

Journal Articles

Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy

Blood (2022) 140 (Supplement 1): 1770–1772.

https://doi.org/10.1182/blood-2022-159976

Published: 2022

Journal Articles

Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Andrew J Davies, Josh Caddy, Katy McLaughlin, Christopher Wignall, Robert Waugh, Graham P. Collins, Louise Stanton, Geoff N Saunders, Thomas Cummin, Anna Schuh, Kirit M. Ardeshna, Andrew K. McMillan, John Radford, David John Lewis, Adam R Coleman, Gareth Griffiths, Cathy Burton, Sharon Barrans, Peter Johnson

Blood (2022) 140 (Supplement 1): 9478–9479.

https://doi.org/10.1182/blood-2022-163499

Published: 2022

Journal Articles

Parsimonious Gene Correlation Network Analysis in DLBCL Allows Refined Linkage to Mutation State and Treatment Response

Matthew A Care, PhD MSc, BSc, Sharon Barrans, Michael A Bentley, Ming Wang, Alexandra Clipson, Ming-Qing Du, Cathy H Burton, Josh Caddy, Andrew J Davies, PhD, Peter Johnson, David R Westhead, Reuben M Tooze

Blood (2017) 130 (Supplement 1): 2824.

https://doi.org/10.1182/blood.V130.Suppl_1.2824.2824

Published: 2017

Journal Articles

Longer Term Efficacy and Safety of Subcutaneous Compared with Intravenous Rituximab: Updated Results of the Phase 3 SABRINA Study

Andrew J Davies, FRCP PhD, Biljana Mihaljevic, Santiago Mercadal, MD, Georgi Mihaylov, Sirpa Leppä, Denise Cotting, Klaas Veenstra, Artem Zharkov, Mark Dixon, BSc MSC, Martin Barrett, David Macdonald

Blood (2016) 128 (22): 1103.

https://doi.org/10.1182/blood.V128.22.1103.1103

Published: 2016

Journal Articles

Regulation of B-Cell Receptor Signalling By the Tumour Microenvironment in Chronic Lymphocytic Leukemia (CLL) and Its Impact on Adhesion and miRNA Expression

Matthew D Blunt, PhD, Rachel Dobson, BSc(Hons), Lindsay D Smith, PhD, Jonathan C. Strefford, Pamela B. Conley, PhD, Anjali Pandey, PhD, Andrew J Davies, FRCP PhD, Peter M Johnson, MA, MD, Graham Packham, PhD, Freda K Stevenson, DPhil, Francesco Forconi, MD DM, PhD FRCPath, Greg P Coffey, PhD, Andrew J Steele, PhD

Blood (2016) 128 (22): 351.

https://doi.org/10.1182/blood.V128.22.351.351

Published: 2016

Journal Articles

Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study

Robert E Marcus, Andrew J Davies, FRCP PhD, Kiyoshi Ando, Wolfram Klapper, MD, Stephen Opat, MD, Carolyn J Owen, Elizabeth H Phillips, Randeep Sangha, Rudolf Schlag, John F Seymour, William Townsend, Marek Trněný, Michael K Wenger, Günter Fingerle-Rowson, Kaspar Rufibach, Tom Moore, Michael Herold, Wolfgang Hiddemann, MD

Blood (2016) 128 (22): 6.

https://doi.org/10.1182/blood.V128.22.6.6

Published: 2016

Journal Articles

Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas

Michelle A Fanale, MD, Steven M Horwitz, MD, Andres Forero-Torres, MD, Nancy L Bartlett, MD, Ranjana H Advani, MD, Barbara Pro, MD, Robert W Chen, MD, Andrew J Davies, FRCP PhD, Tim Illidge, PhD, Mayur Uttarwar, Dirk Huebner, MD, Hong Ren, MD, Andrei R Shustov, MD

Blood (2016) 128 (22): 2993.

https://doi.org/10.1182/blood.V128.22.2993.2993

Published: 2016

Journal Articles

Post Relapse Survival Rates in Diffuse Large B-Cell Lymphoma

Andrew McMillan, PhD, Alejandro Martín, MD PhD, Corinne Haioun, MD PhD, Annalisa Chiappella, Alice Di Rocco, MD PhD, Antonio Rueda, Christina Palaska, Andrew J Davies, FRCP PhD

Blood (2016) 128 (22): 4204.

https://doi.org/10.1182/blood.V128.22.4204.4204

Published: 2016

Journal Articles

A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

Andrew J Davies, MRCP PhD, Josh Caddy, Tom Maishman, Sharon Barrans, PhD, Christoph Mamot, MD, Matthew Care, PhD, Christopher Pocock, Louise Stanton, PhD, Debbie Hamid, Keith Pugh, PhD, Andrew McMillan, PhD, Paul Fields, MDPhD, Anton Kruger, Andrew Jack, PhD MB, Peter W. M. Johnson, FRCP

Blood (2015) 126 (23): 812.

https://doi.org/10.1182/blood.V126.23.812.812

Published: 2015

Journal Articles

Frontline Treatment of CD30+ Peripheral T-Cell Lymphomas with Brentuximab Vedotin in Combination with CHP: 3-Year Durability and Survival Follow-up

Steven M Horwitz, MD, Andrei R. Shustov, MD, Andres Forero-Torres, Nancy L Bartlett, MD, Ranjana Advani, Barbara Pro, Robert Chen, Andrew J Davies, MRCP, Tim Illidge, Dirk Huebner, Dana A. Kennedy, Michelle A. Fanale

Blood (2015) 126 (23): 1537.

https://doi.org/10.1182/blood.V126.23.1537.1537

Published: 2015

Journal Articles

The Syk\Jak Inhibitor Cerdulatinib (PRT062070) Shows Promising Preclinical Activity in Chronic Lymphocytic Leukemia By Antagonising B Cell Receptor and Microenvironmental Signalling

Matthew D Blunt, PhD, Jack Parnell, BSc(hons), Marta Larrayoz, PhD, Lindsay Smith, PhD, Rachel Dobson, BSc(Hons), Jonathan C Strefford, PhD, Freda K Stevenson, DPhil, Francesco Forconi, MD DM, PhD FRCPath, Andrew J Davies, MRCP, Peter W Johnson, MD, Graham Packham, PhD, Greg P. Coffey, PhD, Mark S Cragg, PhD, Andrew J Steele, PhD

Blood (2015) 126 (23): 1716.

https://doi.org/10.1182/blood.V126.23.1716.1716

Published: 2015

Journal Articles

Real-Time Molecular Classification of Diffuse Large B-Cell Lymphoma (DLBCL) By Gene Expression Profiling (GEP): Successful Delivery of a Routine Service for Randomization of Patients Onto the Multicenter Remodl-B Trial (ISRCTN 51837425)

Barrans Sharon, PhD, Andrew J Davies, MRCP, Ming Wang, Ming-Qing Du, MB, PhD, Christoph Mamot, MD, Keith Pugh, PhD, Josh Caddy, Matthew A Care, PhD, Jan Taylor, Reuben M Tooze, PhD FRCP, Tom Maishman, Louise Stanton, PhD, Debbie Hamid, Andrew McMillan, PhD, Paul Fields, MD PhD, Andrew Jack, PhD MB, Peter Johnson, MD

Blood (2015) 126 (23): 331.

https://doi.org/10.1182/blood.V126.23.331.331

Published: 2015

Journal Articles

Defining Immune Response Signatures in DLBCL As Potential Predictive Biomarkers for Outcome to Immunotherapy

Matthew A Care, PhD, Stephen M Thirdborough, PhD, Andrew J Davies, MRCP PhD, Peter W.M. Johnson, FRCP, Andrew Jack, PhD MB, Sharon Barrans, PhD, David R Westhead, PhD, Mark S Cragg, PhD, Reuben M Tooze, PhD FRCP, Stephen A Beers, PhD

Blood (2015) 126 (23): 2663.

https://doi.org/10.1182/blood.V126.23.2663.2663

Published: 2015

NARROW

The high-grade B-cell lymphomas: double hit and more

Delays to Diagnosis of Peripheral T-Cell Lymphoma and Clinical Utility of Molecular Profiling: A UK Multicentre Real-World Study

Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK

PET-Based Prognostic Stratification in Primary Mediastinal B-Cell Lymphoma Using the SUV≥4 Segmentation Threshold: A Comparative Analysis of Contouring Methods in the IELSG37 Trial Cohort

Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

Golseek-2: A Phase 2 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma

Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy

Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Parsimonious Gene Correlation Network Analysis in DLBCL Allows Refined Linkage to Mutation State and Treatment Response

Longer Term Efficacy and Safety of Subcutaneous Compared with Intravenous Rituximab: Updated Results of the Phase 3 SABRINA Study

Regulation of B-Cell Receptor Signalling By the Tumour Microenvironment in Chronic Lymphocytic Leukemia (CLL) and Its Impact on Adhesion and miRNA Expression

Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study

Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas

Post Relapse Survival Rates in Diffuse Large B-Cell Lymphoma

A Prospective Randomised Trial of Targeted Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) Based upon Real-Time Gene Expression Profiling: The Remodl-B Study of the UK NCRI and SAKK Lymphoma Groups (ISRCTN51837425)

Frontline Treatment of CD30+ Peripheral T-Cell Lymphomas with Brentuximab Vedotin in Combination with CHP: 3-Year Durability and Survival Follow-up

The Syk\Jak Inhibitor Cerdulatinib (PRT062070) Shows Promising Preclinical Activity in Chronic Lymphocytic Leukemia By Antagonising B Cell Receptor and Microenvironmental Signalling

Real-Time Molecular Classification of Diffuse Large B-Cell Lymphoma (DLBCL) By Gene Expression Profiling (GEP): Successful Delivery of a Routine Service for Randomization of Patients Onto the Multicenter Remodl-B Trial (ISRCTN 51837425)

Defining Immune Response Signatures in DLBCL As Potential Predictive Biomarkers for Outcome to Immunotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only